Core Viewpoint - The company announced clinical data for its core product, Tengogatinib, in treating advanced cholangiocarcinoma (CCA) patients at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [1] Group 1: Clinical Data Presentation - Tengogatinib, a novel FGFR inhibitor, shows potential activity in overcoming acquired resistance to previous FGFR inhibitors in CCA patients [1] - The report includes an analysis of circulating tumor DNA (ctDNA) biomarkers to evaluate the efficacy of Tengogatinib in patients with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - The study assessed genomic alterations in patient ctDNA and correlated efficacy based on ctDNA mutation status and patient subgroups [1] Group 2: Ongoing Research - The results support further investigation in ongoing Phase III clinical trials by expanding biomarker sampling for deeper analysis [1]

Core Viewpoint - The company announced the presentation of clinical data for its core product, Tengogatinib, at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, highlighting its potential in treating advanced cholangiocarcinoma (CCA) patients [1] Group 1: Clinical Data Presentation - Tengogatinib, a novel FGFR inhibitor, shows promising activity in overcoming acquired resistance to previous FGFR inhibitors in CCA patients with FGFR2 alterations [1] - The report includes an analysis of circulating tumor DNA (ctDNA) biomarkers to evaluate the efficacy of Tengogatinib in patients with primary and acquired resistance to FGFR inhibitors, as well as other FGFR mutations or wild-type FGFR [1] - The assessment of genomic alterations in patient ctDNA and the correlation of efficacy based on ctDNA mutation status and patient subgroups were discussed, supporting further research in ongoing Phase III clinical trials [1]

Core Viewpoint - The company announced the presentation of clinical data for its core product, Tienogratinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [1] Group 1 - The clinical data was presented in a poster format, indicating a significant step in the company's research and development efforts [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 自願性公告 於2026年美國臨床腫瘤學會胃腸道腫瘤研討會公佈 替恩戈替尼單藥治療晚期膽管癌患者的臨床數據 本公告由藥捷安康（南京）科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東及潛在投資者提供有關本集團的最新業務進 展。 本公司董事會（「董事會」）欣然宣佈，本公司在2026年美國臨床腫瘤學會胃腸道腫 瘤研討會(ASCO GI)上以壁報形式公佈了核心產品替恩戈替尼單藥治療晚期膽管 癌(CCA)患者的臨床數據。 題目：替恩戈替尼在晚期膽管癌中的II期研究：分子應答與耐藥機制分析 展示形式：壁報 壁報編號：Bd D9 承董事會命 藥捷安康（南京）科技股份有限公司 董事長兼首席執行官 展示時間：202 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥捷安康 (南京 )科技股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02617 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median stock price increase for the top 10 innovative drug companies was 57.9%, while in 2025, this surged to a median increase of 495.41%, with the highest increase reaching 1824% [2] Group 1: Top Performing Companies - The top-performing stock in 2025 was Beihai Kangcheng, with an astonishing annual increase of 1824%, surprising many in the market [4] - Following Beihai Kangcheng, the second highest was Sanleaf Biotech, which saw an increase of 870%, despite facing significant operational challenges [10] - Yaojie Ankang ranked third with a 773% increase, although its valuation raised concerns due to its limited clinical progress [12] - Heber Pharmaceuticals achieved a 553% increase, driven by its dual-engine model of R&D and business development [16] - Xuan Bamboo Biotech, a newly listed company, experienced a 507% increase, attributed to its new stock status and positive clinical data [20] Group 2: Market Dynamics and Trends - The market has seen a trend of speculative trading, with some companies experiencing price surges not necessarily backed by fundamental improvements [4] - The rise of companies like Heber Pharmaceuticals and Rongchang Biotech illustrates that long-term undervalued firms can achieve significant valuation recovery through continuous R&D and commercialization breakthroughs [4][30] - The innovative drug sector's growth is heavily influenced by liquidity and market sentiment, with many price increases based on speculative expectations rather than solid fundamentals [39] Group 3: Company-Specific Developments - Beihai Kangcheng's stock price recovery was linked to strategic capital injections, resolving its cash flow crisis [7] - Sanleaf Biotech's stock price rebound was primarily driven by its RSV vaccine pipeline, despite facing significant financial pressures [10][11] - Yaojie Ankang's rapid valuation increase raised questions about its sustainability, given its limited clinical advancements [13][14] - Heber Pharmaceuticals' growth was supported by strategic partnerships and a robust technology platform, enhancing investor confidence [18][19] - Rongchang Biotech's stock performance was bolstered by successful product approvals and strategic financing, improving its market outlook [31]

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median increase for the top 10 innovative drug companies was 57.9%, with the highest increase reaching 132.6%. In 2025, this trend intensified, with the median increase for the top 10 soaring to 495.41% and the highest increase hitting 1824% [2] Group 1: Top Performing Companies - Beihai Kangcheng-B achieved the highest increase in 2025, with a staggering 1824% rise, surprising many in the market [5] - Sanleaf Biotech-B followed with an impressive 870% increase, despite facing significant operational challenges, including a cash flow crisis and a major refund demand from GAVI [10][11] - Yaojie Ankang-B, despite being controversial, saw its stock price rise nearly ninefold in a short period, reaching a market cap close to 270 billion HKD [12][13] - Heptagon Pharmaceuticals-B ranked fourth with a 553% increase, driven by its dual-engine model of R&D and business development [14][15] - Xuan Bamboo Biotech-B, a newly listed company, achieved a 507% increase, benefiting from positive clinical trial results and inclusion in national insurance directories [17][18] - Deqi Pharmaceuticals-B saw a 483% increase, attributed to its innovative AI-driven T-cell connector platform [19][20] - Jike Si-B experienced a 401% increase, driven by its advancements in KRAS-targeted therapies [22][23] - Rongchang Biotech achieved a 400% increase, with its product Taite Xip demonstrating significant potential across multiple indications [24][25] - Paige Biotech saw a 342% increase, largely due to its GLP-1 pipeline's market momentum [27] - Baiaosaitu-B rounded out the top ten with a 315% increase, supported by strong revenue growth and positive market expectations for its upcoming H+A listing [28][30] Group 2: Market Dynamics - The surge in stock prices for many companies is not solely based on fundamental improvements but also reflects speculative trading behaviors [4] - The innovative drug sector's long-term health relies on the emergence of stocks driven by genuine innovation rather than short-term speculation [4] - The market's focus on liquidity and sentiment has led to significant price increases, but these may not be sustainable as market conditions change [31]

Group 1 - The Shenzhen Securities Information Company has not provided an explanation regarding the inclusion of Yaojie Ankang in the index, despite several months having passed since the event [2][3][7] - There is a growing concern among investors about the lack of communication from the Shenzhen Securities Information Company, which is seen as a critical infrastructure in China's capital market [4][8] - Investors are urging the company to take responsibility and communicate transparently about the situation to foster the development of index-based investments in China [4][8] Group 2 - Yaojie Ankang's market capitalization experienced significant fluctuations, rising to nearly 270 billion HKD before rapidly declining to approximately 60 billion HKD [6] - The company's stock price saw dramatic changes, with a rise of 77% followed by a drop of 54% within a short period, indicating high volatility in the market [6][7] - The inclusion of Yaojie Ankang in multiple indices has drawn widespread attention and concern from the market, highlighting the impact of index inclusion on stock performance [6][7]

Core Viewpoint - The stock of药捷安康-B (02617.HK) has experienced a significant decline, dropping over 14% to 145 HKD with a trading volume of 163 million HKD [2] Group 1 - The stock price of药捷安康-B fell by 14.05% [2] - The current trading price is reported at 145 HKD [2] - The total trading volume reached 163 million HKD [2]

Core Viewpoint - The stock of药捷安康-B (02617) has dropped over 14% due to the unlocking of cornerstone shares, with a total of 9.774 million shares being released from lock-up [1] Group 1: Stock Performance - As of the report, the stock price of药捷安康-B is down 14.05%, trading at 145 HKD, with a transaction volume of 163 million HKD [1] - The stock reached a historical high of 679.5 HKD per share in mid-September, representing an increase of nearly 51 times from its initial public offering price of 13.15 HKD on June 23 [1] Group 2: Share Unlocking Details - The unlocking event occurred on December 23, involving five shareholders and a total of 9.774 million shares [1] - The market had previously shown significant interest in药捷安康, with its market capitalization approaching 270 billion HKD at its peak [1]